Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients

Despite the efficacy of decitabine to myelodysplastic syndrome (MDS), there is a wide range of responses, and no definite predictive marker has been identified. This study aimed to describe the efficacy of decitabine and to identify potential predictors of response and survival in patients with MDS....

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Jung, Hyun Ae, Maeng, Chi Hoon, Kim, Moonjin, Kim, Sungmin, Jung, Chul Won, Jang, Jun Ho
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2015
Témata:
Clinical Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4599296/
https://ncbi.nlm.nih.gov/pubmed/25938546
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky